CTBO (Cantabio Pharmaceuticals) Net Income From Continuing Operations: $-1.54 Mil (TTM As of Dec. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cantabio Pharmaceuticals Net Income From Continuing Operations?

Cantabio Pharmaceuticals CTBO Net Income From Continuing Operations is $-1.54 Mil as of Dec. 2018.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cantabio Pharmaceuticals's net income from continuing operations for the three months ended in Dec. 2018 was $0.34 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2018 was $-1.54 Mil.

Cantabio Pharmaceuticals Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Net Income From Continuing Operations Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Net Income From Continuing Operations
Get a 7-Day Free Trial -0.09 -0.03 -0.75 -1.11 -2.01

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.46 -0.85 -0.47 -0.57 0.34

Cantabio Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-1.54 Mil mean?
Cantabio Pharmaceuticals (CTBO) has a Net Income From Continuing Operations of $-1.54 Mil as of Dec. 2018. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Net Income From Continuing Operations too high?
Cantabio Pharmaceuticals' current Net Income From Continuing Operations is $-1.54 Mil.
How does Cantabio Pharmaceuticals' Net Income From Continuing Operations compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Net Income From Continuing Operations of $-1.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current Net Income From Continuing Operations is $-1.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Net Income From Continuing Operations of $-1.54 Mil. The current Net Income From Continuing Operations is $-1.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Net Income From Continuing Operations is $-1.54 Mil as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc. is a preclinical-stage biotechnology company based in the United States. It focuses on developing and commercializing novel therapies and intellectual property for neurodegenerative conditions, principally Parkinson's disease and Alzheimer's disease, as well as related disorders. Its research centers on therapeutic proteins designed to cross the blood-brain barrier and restore in vivo levels of proteins that lose function under disease conditions. The company's pipeline targets the underlying protein dysfunction associated with neurodegeneration rather than merely treating symptoms. As a preclinical-stage enterprise, Cantabio does not yet market approved products and generates no product revenue; its activities center on research and development, patent generation, and seeking partnerships or licensing arrangements to advance its drug candidates toward clinical testing. Its operations and intellectual property are based primarily in the United States.